Project Grant R35GM156197
Award Date 9/1/25
Completion Date 7/31/30
Dollars Obligated $410K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rhode Island, USA
Similar Awards
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $418,750.00 to The Feinstein Institutes for Medical Research to conduct research on T cell receptor-mediated T cell activation in neonatal and pediatric sepsis. The goal is to gain insight into how T cell memory influences sepsis-associated organ dysfunction, by comparing responses between human neonates with sepsis and...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to compare the regulated and dysregulated host immune responses to infection in mice and humans. The $162,000 award to The Feinstein Institutes For Medical Research will investigate differences in IL-10 signaling by T cells as a potential factor distinguishing the regulated immune response to uncomplicated infection...
- The Research Foundation for the State University of New York received a $108,512 Project Grant from the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training program) to develop novel immune-modulating itaconate-loaded telodendrimer nanoparticles to target both hyperinflammation and pyroptosis in sepsis. The project aims to address the current gap in therapies that can directly mitigate excessive cytokine production and immune cell pyroptosis,...
- This $479,249 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to understand the molecular mechanisms regulating neutrophil proinflammatory and adhesive activities in sepsis. The project aims to investigate the role of neutrophil A20 signaling in contributing to organ damage in sepsis. Specifically, the research will: 1) Determine the molecular...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $473,937 Project Grant to The General Hospital Corporation (d/b/a Massachusetts General Hospital) for the project "Novel Point-of-Care Liquid Biopsy for Early Detection of Sepsis-Associated Organ Damage". The project aims to develop a novel circulating cellular biomarker for the early detection and assessment of...
- This federal Project Grant award of $489,500.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of the ADB2 complement receptor in acute lung injury associated with sepsis. The primary objectives are to: 1) Determine the binding profile of ADB2 to different complement fragments and its contribution to leukocyte binding; and 2) Delineate the mechanism by which ADB2 regulates...
- This federal Project Grant award of $423,500.00, provided by the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program, aims to address two critical challenges related to burn sepsis: Identifying distinct immune response phenotypes after burn injury and their relation to sepsis development, in order to enable novel approaches to mitigate sepsis risk. Determining the mechanism by which elevated angiopoietin-2 (ANGPT-2) leads...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Temple University provides $683,299 to conduct research on the functional immune phenotypes of sepsis patients. The project aims to integrate microphysiological assays, omics data, and in silico modeling to better understand how different neutrophil subpopulations and their interactions with the vascular endothelium contribute to sepsis-induced organ dysfunction....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $197,640 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), on July 16, 2025. This grant supports research to investigate the contribution of a novel monocyte transcriptional state, termed Monocyte Substate 1 (MS1), to sepsis immunopathogenesis and patient heterogeneity. The project will...
- This Project Grant award of $455,000 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to decrease sepsis mortality in the pediatric population. The key products and services to be delivered include: Developing an AI-guided early sepsis identification tool to enable timely diagnosis and treatment. Performing sepsis phenotyping and creating digital twin patient models to predict personalized treatment responses....